Navigation Links
Archemix Announces Completion of Phase 1 Trial of ARC1779

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - Archemix Corp., a biotechnology company focused on discovering and developing aptamers, announced the successful completion of a Phase 1 study of its novel aptamer therapeutic, ARC1779. ARC1779 is designed to selectively block the activation, adhesion and aggregation of platelets by inhibiting the binding of von Willebrand Factor (vWF) to the GPIb receptor on platelets. Activated vWF is scientifically recognized as the first stage of arterial thrombus formation and plays a significant role in the development of harmful blood clots. Archemix plans to develop ARC1779 as an anti-thrombotic drug for use in angioplasty and in a rare blood disorder that is mediated by vWF known as thrombotic thrombocytopenic purpura, or TTP.

Archemix plans to present a complete data set from this Phase 1 clinical trial within a peer-reviewed forum in 2007.

Based on the proof-of-mechanism data from this Phase 1 study, Archemix plans to commence a Phase 2 study of ARC1779 to evaluate the safety and efficacy of ARC1779 in acute coronary syndrome patients during the fourth quarter of 2007. Additionally, Archemix plans to initiate a Phase 1b study of ARC1779 in patients suffering from TTP in the fourth quarter of 2007. Approximately 3,000 new cases of TTP are diagnosed per year in the United States, but currently there is no approved drug therapy for the disease.

"We are very pleased to demonstrate ARC1779 can inhibit vWF activation and platelet function, which are both widely recognized as playing critical roles in clot formation which can critically impede blood flow to the heart," said Jim Gilbert, M.D., Chief Medical Officer, Archemix. "In Phase 2, we hope to show that using ARC1779 during angioplasty may improve myocardial perfusion by reducing blood clots in the coronary microcirculation while also providing effective anti-thrombotic treatment at the primary site of arte
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Archemix Announces Completion Phase Trial ARC1779
(Date:5/23/2013)... , May 23, 2013  Texas, premier physician ... deliver doctors the survival tools they need to provide ... in today,s health care marketplace. "I am ... save local practices," said Stephen L. Brotherton ... (TMA). " Texas doctors are determined ...
(Date:5/23/2013)... 23, 2013   Direct to implant, or ... an appropriate option for many women with BRCA ... their breast cancer risk, or with breast cancer. ... and a second surgery to insert permanent implants, ... surgery as mastectomy can be a medically and ...
(Date:5/23/2013)...  BioElectronics Corporation (OTC Pink: BIEL), the maker of ... FDA panel meeting for non-thermal shortwave diathermy: ... Therapy Meeting was held on May 21, 2013 in ... of the meeting was very narrow, in that the ... the application of non-thermal shortwave diathermy for the treatment ...
Breaking Medicine Technology:TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2
... Data presented,today at a major medical meeting found ... five days is as,effective as standard therapy of ... of complicated urinary tract infections,(cUTI) and acute pyelonephritis ... LEVAQUIN in the,U.S., presented the data during a ...
... Pressure in Obese and,Non-Obese Hypertensive Patients, CHICAGO, ... today presented positive data from two clinical,studies ... selective beta,1-blocker with vasodilating properties currently under ... (FDA) for the treatment of,hypertension. Data from ...
Cached Medicine Technology:Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 2Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 3Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 4
(Date:5/24/2013)... week is National EMS Week, which recognizes and honors ... emergency care and to improve health communications in communities. ... the public that all can play a role in ... and a very important one. According to the American ... can triple a victim’s chance of survival. , Fortunately ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Patients hospitalized for ... if they,re admitted on Mondays or in the morning, ... of stay are highest among heart failure patients admitted ... researchers, who are scheduled to present their findings Saturday ... Failure Association of the European Society of Cardiology. ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 KC and Monica ... Title Sponsors for FreeRide836. Their oldest sons, Kyle and Austin ... Tracey Russell family and several professional kiteboarders. , KC Craichy ... project. "This has miraculously come together such that virtually everyone ... to participate." , 20 kite boarders will meet at Matheson ...
(Date:5/24/2013)... research suggests a link between sleep duration and ... additional hour someone with insomnia sleeps is associated ... of moderate or high risk of suicide, according ... "We were surprised by the strength of ... study author, Linden Oliver, clinical research coordinator for ...
(Date:5/24/2013)... Portland, OR (PRWEB) May 24, 2013 ... and Sustainable Cards, major competitors in sustainable card ... awareness of using forest materials as a sustainable ... committee is to identify industry challenges and increase ... gift card programs to support the reduction of ...
Breaking Medicine News(10 mins):Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3
... single-institution study of its kind has found few complications ... to remove the prostate. Men in this study received ... indicated their cancer had recurred. Researchers ... and Minnesota suggest that patients and their physicians should ...
... Epigenetics of Common Human Disease has been chosen as ... Institutes of Health (NIH) grant for Centers of Excellence ... $16.8 million over five years. "We,re grateful ... understanding how epigenetic control affects disease," says the center,s ...
... higher, research finds , MONDAY, Sept. 28 (HealthDay News) ... the autoimmune condition called antiphospholipid syndrome are at greatly ... risk is even higher when these women smoke or ... syndrome occurs when autoantibodies attach to cell membranes and ...
... be serious, study finds , MONDAY, Sept. 28 (HealthDay ... skin lesions that are harmless in most cases but ... a new study suggests. , Researchers examined 320 people ... Of those, 7.5 percent developed skin lesions as a ...
... isn,t clear, researchers say , , MONDAY, Sept. 28 ... a 26 percent increased risk of developing atrial fibrillation, ... The overall incidence of atrial fibrillation was 3.6 percent ... for people without the metabolic condition was only 2.5 ...
... have used nanomaterials to develop a microchip sensitive enough ... patient,s cancer so that the disease can be detected ... reported Sept. 27 in Nature Nanotechnology heralds ... "This remarkable innovation is an indication that the ...
Cached Medicine News:Health News:Mayo researchers find few side effects from radiation treatment given after prostate cancer surgery 2Health News:Mayo researchers find few side effects from radiation treatment given after prostate cancer surgery 3Health News:Autoimmune Disorder Linked to Stroke, Heart Attack in Women 2Health News:Irregular Heartbeat Risk Higher in Women With Type 2 Diabetes 2Health News:Irregular Heartbeat Risk Higher in Women With Type 2 Diabetes 3Health News:U of T researchers create microchip that can detect type and severity of cancer 2
... Quebec Colony Counter allows the user to quickly ... models allows for digital counting or manual counting. ... standard lens increasing magnification to 3.0X. The adjustable ... be raised or lowered. The lens also rotates ...
The Accucount 1000 is designed to automatically count macroscopic objects in a field displaying totals on a highly visible digital readout....
... is a Accelerated Bacterial Enumeration System. Bacterial ... of colonies found by the volume dispensed ... A logarithmically decreasing volume of sample is ... Petri dish in an Archimedes spiral. The ...
... automated genetic analysis system. This system automatically ... linear polyacrylamide (LPA) gel, denatures and loads ... analyzes the data. Software tools let you ... automated data assessment. All to ensure unprecedented ...
Medicine Products: